A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab
Abroad (travel likely)Recruiting
Conditions
Cardiovascular Diseases · Atherosclerotic Cardiovascular Disease · Hypercholesterolemia, Familial
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Novartis, Basel, Switzerland
Study leads
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals